In the last trading session, 3.92 million Tscan Therapeutics Inc (NASDAQ:TCRX) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $1.21 changed hands at -$0.03 or -2.42% during last session, the market valuation stood at $68.47M. TCRX’s last price was a discount, traded about -700.83% off its 52-week high of $9.69. The share price had its 52-week low at $1.02, which suggests the last value was 15.7% up since then.
Analysts gave the Tscan Therapeutics Inc (TCRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TCRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Tscan Therapeutics Inc (NASDAQ:TCRX) trade information
Instantly TCRX was in red as seen at the end of in last trading. With action -9.02%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -60.20%, with the 5-day performance at -9.02% in the red. However, in the 30-day time frame, Tscan Therapeutics Inc (NASDAQ:TCRX) is -20.92% down.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 59.67% from its current market value. According to analyst projections, TCRX’s forecast low is 3 with 3 as the target high. To hit the forecast high, the stock’s price needs a -147.93% plunge from its current level, while the stock would need to soar -147.93% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -14.41%. The 2025 estimates are for Tscan Therapeutics Inc earnings to decrease by -9.10%, but the outlook for the next 5-year period is at 9.18% per year.
TCRX Dividends
Tscan Therapeutics Inc is expected to release its next quarterly earnings report in June.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 4.4082% or 5.0 million shares worth $29.25 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust . With 1.37 shares estimated at $1.66 million under it, the former controlled 2.62% of total outstanding shares. On the other hand, BlackRock Health Sciences Term Trust held about 2.00% of the shares, roughly 1.05 shares worth around $1.27 million.
